Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Cumberland Vaults on DMD Test Results
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares began Tuesday sharply higher. Cumberland, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...
Cumberland reports progress in DMD heart disease trial
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...
ETF Daily News18d
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care ...
ETF Daily News26d
StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care ...
ADVFN26d
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United ...
Yahoo Finance22d
3 US Penny Stocks With Market Caps Over $30M
Overview: Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that acquires, develops, and commercializes prescription products for hospital acute care, gastroenterology ...